Research Use Only - Not for human consumption. 18+ only.
DGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlySpecialized PeptidesIntravenous (IV) — for monoclonal antibody inhibitorsSubcutaneous (SC) — for some peptide antagonists and receptor constructs

Myostatin

Also known as: GDF-8, Growth Differentiation Factor 8

Myostatin (GDF-8) is a naturally occurring myokine that negatively regulates skeletal muscle growth and development. Research focuses on myostatin inhibition as a therapeutic strategy for muscle wasting diseases, sarcopenia, and age-related muscle loss. Direct myostatin administration is not clinically used; research emphasizes inhibitors and antagonists.

Beginner Basics

Plain-English guide to Myostatin

What it does

Myostatin is a natural brake that stops muscle growth in your body. Researchers study ways to block this brake so muscles can grow bigger and stronger, especially to help people with muscle-wasting diseases or aging-related muscle loss.

Typical dose

There is no standard direct myostatin dose because it's not used by itself. Researchers instead use myostatin blockers (inhibitors), which vary widely depending on the type-typically given as injections ranging from small weekly doses to larger monthly doses depending on the specific blocker being studied.

When to inject

Timing depends on the specific myostatin blocker being used. Follow the research protocol or medical guidance for your particular compound, as different inhibitors have different optimal dosing schedules.

Storage

Store the dry powder in a cool, dark place (2-8°C) away from light until you're ready to mix it. Once mixed with liquid, keep it refrigerated and use it within the timeframe specified by your supplier.

First-timer tip

Myostatin blockers are specialized research compounds with varying formulations-don't assume all myostatin inhibitors work the same way or use the same dose, so always follow the specific instructions for whichever blocker you're working with.

Research Status

DGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only

Myostatin inhibitors are in active clinical development for muscle wasting diseases, sarcopenia, and muscular dystrophies. Multiple monoclonal antibodies and soluble receptor constructs have entered Phase II/III trials. Direct myostatin peptide administration is not used clinically; research focuses on antagonists and inhibitors.

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Increases skeletal muscle mass and strength
Prevents and reverses muscle wasting
Improves muscle regeneration after injury
Reduces age-related sarcopenia progression
Enhances muscle protein synthesis
Supports recovery from cachexia
Improves physical function in elderly populations

Side Effects

Injection site reactions (redness, swelling, itching)
CommonMild

Typically resolve within 24–48 hours. Rotate injection sites to minimize recurrence. Apply ice if swelling persists. Use a new needle for each injection and ensure proper sterile technique.

Transient local pain or discomfort at injection site
CommonMild

Usually mild and brief. Allow the solution to reach room temperature before injection. Ensure the needle is sharp and properly inserted. Slow injection (3–5 seconds) reduces discomfort.

Lipodystrophy (localized fat loss or thickening)
UncommonModerate

Develops with repeated injections in the same site. Prevent by rotating injection sites systematically. Maintain at least 1 inch between injection points. If lipodystrophy develops, avoid that area for 2–3 months.

Headache
UncommonMild

May occur in the first few days of use. Usually self-resolving. Stay well hydrated and take over-the-counter analgesics if needed.

Nausea or mild gastrointestinal upset
UncommonMild

Typically transient. Take the injection with food if tolerated. Discontinue if severe or persistent.

Fatigue or lethargy
UncommonMild

May occur during the first 1–2 weeks as the body adapts. Usually resolves spontaneously. Ensure adequate sleep and hydration.

Joint or muscle aches
UncommonMild

May reflect increased muscle protein synthesis and adaptation. Typically mild and self-limiting. Ensure adequate recovery and hydration.

Allergic reaction (rash, urticaria, angioedema)
RareSerious

Seek immediate medical attention if severe. Mild rash may respond to antihistamines. Discontinue use if allergic symptoms develop. Do not re-inject if prior allergic reaction occurred.

Anaphylaxis
RareSerious

Medical emergency. Seek immediate emergency care. Have epinephrine available if you have a history of severe allergies. Discontinue use permanently if anaphylaxis occurs.

Dosing Reference

ParameterValue
Dose range-
Frequency, timing and route - members only

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2-8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Molecular weight26000

Myostatin is a TGF-β superfamily member that acts as a negative regulator of muscle mass by binding to activin type II receptors (ActR2B) on muscle cells, suppressing myogenic differentiation and protein synthesis. Inhibition of myostatin signaling removes this brake on muscle growth, allowing increased muscle protein synthesis and hypertrophy. Research explores myostatin inhibitors (monoclonal antibodies, soluble receptors, and antagonistic peptides) rather than myostatin itself as therapeutic agents.

Pathways and mechanism detail available to members

Track your Myostatin research

Free account. No credit card required.

Start Free

Recent Research

All results

Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Myostatin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.